579486-60-5

Upstream product

• 101079-63-4 3,4-diamino-2,6-dichloropyridine 
• 64-19-7 acetic acid 
• 78-39-7 Triethyl orthoacetate 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 2587-03-3 2,6-dichloro-N-nitro-4-pyridinamine 
• 1445-45-0 Trimethyl orthoacetate 
• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 

Downstream Products

• 1319732-00-7 7-(4-bromobutyl)-2-chloro-6-benzyloxy-8-methylimidazo[4,5-c]pyridine 
• 1319732-01-8 9-(4-bromobutyl)-2-chloro-6-benzyloxy-8-methylimidazo[4,5-c]pyridine 
• 1319732-02-9 7-(4-methoxybutyl)-2-chloro-6-benzyloxy-8-methylimidazo[4,5-c]pyridine 
• 1319732-03-0 9-(4-methoxybutyl)-2-chloro-6-benzyloxy-8-methylimidazo[4,5-c]pyridine 
• 579486-66-1 2-(3,4-dichlorobenzylamino)-7-(4-methoxybutyl)-8-methyl-6-oxo-3-deazapurine 
• 1319732-04-1 2-(3,4-dichlorobenzylamino)-9-(4-methoxybutyl)-8-methyl-6-oxo-3-deazapurine 
• 1319731-99-1 2-chloro-6-benzyloxy-8-methylimidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

CDK INHIBITORS

Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.

AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS

The present invention relates to azabenzimidazole derivatives of Formula (I) (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active 10 ingredient as well as the use of said compounds as a medicament.

7-Alkyl-N2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity

Several 2-anilino- and 2-benzylamino-3-deaza-6-oxopurines [3-deazaguanines] and selected 8-methyl and 8-aza analogs have been synthesized. 7-Substituted N2-(3-ethyl-4-methylphenyl)-3-deazaguanines were potent and selective inhibitors of Gram+ bacterial DNA polymerase (pol) IIIC, and 7-substituted N2-(3,4-dichlorobenzyl)-3-deazaguanines were potent inhibitors of both pol IIIC and pol IIIE from Gram+ bacteria, but weakly inhibited pol IIIE from Gram- bacteria. Potent enzyme inhibitors in both classes inhibited the growth of Gram+ bacteria (MICs 2.5-10 μg/ml), and were inactive against the Gram- organism Escherichia coli. Several derivatives had moderate protective activity in Staphylococcus aureus-infected mice.

Purine and isosteric antibacterial compounds

The invention features 2,7-disubstituted purines and their isosteres such as the corresponding 3-deazapurines and 3-deaza-8-azapurines. The compounds disclosed herein have potent anti-microbial, e.g., anti-bacterial and anti-mycoplasmal properties. The compounds described herein inhibit DNA polymerase IIIC and DNA polymerase IIIE species; the compounds thus inhibit the growth of bacteria and mycoplasmata. The compounds can be administered to prevent or to treat Gram-positive or Gram-negative bacterial or mycoplasmal infections, e.g., in eukaryotic cell cultures, animals, or humans.